August 2006 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

August 2006

Pharmaceutical Technology


RESTRUCTURING
Pfizer To Phase Out Manufacturing at Groton

Pfizer, Inc. (New York, NY, http://www.pfizer.com/) will phase out manufacturing operations in Groton, Connecticut, eliminating roughly 300 jobs.



The move would allow the company to expand its research and development operations in Groton near the 50-acre manufacturing site. Pfizer's Groton and New London sites in Connecticut are the company's largest research sites, employing roughly 6000 people.

The move is part of Pfizer's company-wide restructuring effort, announced in 2005, under which Pfizer hopes to save $4 billion annually by 2008.

Pfizer plans to begin cutting its Groton manufacturing operations in 2007. The facility makes active ingredients for several pharmaceuticals and animal health products, and the company plans to transfer the manufacture of those products to other plants.
–Patricia Van Arnum

FDA Withdraws 117 Inactive NDAs and ANDAs

Effective June 16, 2006, the US Food and Drug Administration (Rockville, MD, http://www.fda.gov/) withdrew approval of 65 new drug applications (NDAs) and 52 abbreviated new drug applications (ANDAs). The holders of NDAs and ANDAs each notified FDA that their drug products are no longer marketed and requested that the approval of the applications be withdrawn. The applicants waived their opportunity for a hearing. The list is available in the Federal Register (Federal Register 71 [116], [June 16, 2006]).
–Kaylynn Chiarello–Ebner

ACQUISITION
J&J to Buy Pfizer's Consumer Healthcare Business for $16.6 Billion

Johnson & Johnson Company (J&J, New Brunswick, NJ, http://www.jnj.com/) agreed to buy the consumer healthcare business of Pfizer, Inc. (New York, NY, http://www.pfizer.com/) for $16.6 billion in cash.

"This acquisition builds upon our broad base in healthcare products and our leadership objectives in the consumer, pharmaceutical, and medical devices and diagnostics markets," said William C. Weldon, J&J's chairman and CEO, in a company release. Pfizer's consumer healthcare business includes personal care and over-the-counter (OTC) products such as "Zantac," "Sudafed," "Neosporin," and "Benadryl." Overall, the business posted 2005 sales of $3.9 billion. J&J also will acquire the US OTC switch rights to "Zyrtec" (cetirizine), Pfizer's once-a-day, nonsedating prescription antihistamine, upon patent expiration.

Pfizer decided to sell the business following a review of its strategic options that the company had initiated in February. The deal is expected to close by the end of 2006.

Pfizer also announced that during 2006 and 2007, it will purchase as much as $17 billion of the company's stock by using the net proceeds from the sale of its consumer healthcare business and cash from ongoing operations.
–Patricia Van Arnum


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
29%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
13%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Pharmaceutical Technology,
Click here